Loading...
OTCM
VBACY
Market cap3.04bUSD
, Last price  
USD
Name

Virbac SA

Chart & Performance

D1W1MN
OTCM:VBACY chart
P/E
—
P/S
—
EPS
18.01
Div Yield, %
—
Shrs. gr., 5y
-0.11%
Rev. gr., 5y
9.41%
Revenues
1.46b
+4.82%
401,636,000438,548,000443,355,000467,418,000572,830,000623,059,000695,155,000736,080,000773,116,000852,623,000871,828,000861,882,000868,932,000938,342,000934,198,0001,063,965,0001,216,187,0001,246,901,0001,397,380,0001,464,677,000
Net income
151m
+3.85%
24,913,00031,873,00036,287,00039,676,00064,313,00058,555,00066,625,00060,523,00063,596,0009,405,00034,646,000-2,575,00020,099,00051,550,000136,039,000113,162,000121,967,000121,298,000145,290,000150,887,000
CFO
196m
-4.20%
48,807,00050,451,00042,280,00064,778,00083,897,00061,781,00097,033,00073,633,00076,447,00046,221,000142,449,000107,806,00083,623,000131,609,000118,918,000129,904,00098,984,000118,957,000204,221,000195,646,000
Earnings
Sep 10, 2026

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Founded in 1968 and based in Carros, France, Virbac S.A. is a prominent developer and distributor of a wide array of animal health products and services. The company's global operations extend across France, Europe, Latin America, North America, Asia Pacific, the Middle East, and Africa, catering to both domestic companion animals and commercial livestock. Its extensive portfolio encompasses vaccines, dental hygiene products, reproductive health solutions, dermatological treatments, parasiticides, diagnostic instruments, antibiotics, and aquaculture offerings. Furthermore, Virbac supplies specialized veterinary pharmaceuticals for anesthesia, geriatric care, behavioral management, and injectable micronutrients, alongside pet food and electronic identification systems. These diverse solutions are designed to support veterinarians, agricultural producers, and individual pet owners worldwide.
URL
https://corporate.virbac.com/
IPO date
Jan 01, 1985
Employees
5,386
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT